Catalent (NYSE:CTLT) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a research note released on Sunday. The brokerage issued a sell rating on the stock.

A number of other research firms have also weighed in on CTLT. Royal Bank of Canada reissued a sector perform rating and set a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. Barclays boosted their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a report on Friday, June 28th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Catalent currently has an average rating of Hold and a consensus price target of $56.83.

Catalent Trading Up 0.7 %

CTLT opened at $59.80 on Friday. Catalent has a fifty-two week low of $31.80 and a fifty-two week high of $60.20. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. The firm has a market capitalization of $10.82 billion, a price-to-earnings ratio of -9.80, a PEG ratio of 2.47 and a beta of 1.16. The company’s 50 day moving average price is $58.24 and its two-hundred day moving average price is $56.91.

Insider Transactions at Catalent

In other news, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the transaction, the insider now owns 20,617 shares in the company, valued at approximately $1,118,678.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Scott Gunther sold 666 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now owns 39,635 shares in the company, valued at approximately $2,360,264.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the transaction, the insider now owns 20,617 shares in the company, valued at approximately $1,118,678.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,810 shares of company stock worth $858,941. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Truist Financial Corp lifted its position in shares of Catalent by 37.2% during the 2nd quarter. Truist Financial Corp now owns 28,029 shares of the company’s stock valued at $1,576,000 after acquiring an additional 7,600 shares during the period. Millennium Management LLC increased its stake in Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after purchasing an additional 2,299,784 shares in the last quarter. MBB Public Markets I LLC bought a new stake in Catalent during the 2nd quarter valued at $788,000. APG Asset Management N.V. increased its stake in Catalent by 26.8% during the 2nd quarter. APG Asset Management N.V. now owns 155,466 shares of the company’s stock valued at $8,157,000 after purchasing an additional 32,900 shares in the last quarter. Finally, APG Asset Management US Inc. increased its stake in Catalent by 2.3% during the 2nd quarter. APG Asset Management US Inc. now owns 52,861 shares of the company’s stock valued at $2,969,000 after purchasing an additional 1,172 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.